COLUMBUS, Ohio, Oct. 20, 2025 /PRNewswire/ — Orsini, a leader in rare disease pharmacy solutions, announced the launch of its integrated specialty pharmacy and third-party logistics (3PL) solution, supported by the company’s new Columbus, Ohio facility. The launch expands Orsini’s nationwide capabilities and strengthens its ability to deliver end-to-end support for biopharma partners launching rare disease therapies.
Orsini Launches Integrated Specialty Pharmacy and 3PL Solution at Columbus, Ohio Facility
The Columbus facility, now fully operational and licensed to dispense medication in all 50 states, strengthens Orsini’s infrastructure with comprehensive specialty pharmacy redundancy, co-located 3PL capabilities, and advanced ultra-cold storage to support gene and cell therapy programs. By combining specialty pharmacy and 3PL services under one roof, Orsini delivers an integrated model designed specifically for rare disease therapies where Orsini serves as the exclusive specialty pharmacy partner.
“This launch represents more than an expansion — it’s an investment in our mission to improve the lives of patients and families affected by rare diseases,” said Brandon Tom, Orsini’s Chief Executive Officer. “The Columbus facility strengthens our operational platform and enhances our ability to deliver a seamless experience for both patients and partners.”
Orsini’s first exclusive integrated specialty pharmacy and 3PL commercialization partner to be supported by the new facility is Immedica Pharma, a biopharmaceutical company focused on rare disease products.
About Orsini
Providing patients with comprehensive and compassionate care since 1987, Orsini is a leader in rare diseases and gene therapies. Orsini partners with biopharma innovators, healthcare providers and payors to support patients and their families in accessing revolutionary treatments for rare diseases. Through integrated rare disease pharmacy solutions including pharmacy distribution, patient services, clinical management and convenient home infusion services, Orsini simplifies how patients connect to advanced therapies. Orsini’s high-touch care model centers on experienced and trained therapy care teams that provide personalized patient care to ensure that No Patient is Left Behind™.
Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC’s Rare Disease Pharmacy Center of Excellence Designation and ACHC’s Distinction in Rare Diseases and Orphan Drugs. For more information, visit www.orsini.com.
SOURCE Orsini
